MDT-AP-2478
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 5
- sex
- F
- new_clusters
- C5
- umap1_2d
- 3.964095472
- umap2_2d
- 4.747917355
- umap1_3d
- 2.099759822
- umap2_3d
- 0.026907001
- umap3_3d
- -1.337279501
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.370
- INFLAMMATORY_RESPONSE+0.320
- HEDGEHOG_SIGNALING+0.310
- ALLOGRAFT_REJECTION+0.290
- KRAS_SIGNALING_DN+0.290
- PANCREAS_BETA_CELLS+0.260
- KRAS_SIGNALING_UP+0.250
- COMPLEMENT+0.230
- IL6_JAK_STAT3_SIGNALING+0.210
- APICAL_SURFACE+0.170
Top 10 suppressed
- MYC_TARGETS_V2-0.690
- MYC_TARGETS_V1-0.650
- E2F_TARGETS-0.610
- UNFOLDED_PROTEIN_RESPONSE-0.560
- G2M_CHECKPOINT-0.530
- DNA_REPAIR-0.480
- MTORC1_SIGNALING-0.470
- MITOTIC_SPINDLE-0.430
- FATTY_ACID_METABOLISM-0.400
- OXIDATIVE_PHOSPHORYLATION-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1360104 | GTEX | — | 0.921 |
| 2 | SRR1334440 | GTEX | — | 0.917 |
| 3 | MNG1135 | — | — | 0.909 |
| 4 | SRR12202446 | — | — | 0.908 |
| 5 | SRR1486475 | GTEX | — | 0.907 |
| 6 | SRR1397073 | GTEX | — | 0.904 |
| 7 | SRR1487295 | GTEX | — | 0.901 |
| 8 | SRR12202435 | — | — | 0.900 |
| 9 | SRR1475803 | GTEX | — | 0.900 |
| 10 | MDT-AP-2573 | Med | Medulloblastoma | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |